SLAMF7 靶点蛋白|抗体药物|临床药物信息

SLAMF7信息

英文名称：SLAM family member 7
中文名称：SLAM家族成员-7
靶点别称：CS1，UNQ576/PRO1138，SLAMF7，Novel Ly9，SLAM Family Member 7，Membrane Protein FOAP-12，CD2 Subset 1，Protein 19A，CRACC，CD2-Like Receptor Activating Cytotoxic Cells，CD2-Like Receptor-Activating Cytotoxic Cells，19A24 Protein，CD319，19A，CD319 Antigen，Novel LY9 (Lymphocyte Antigen 9) Like Protein

上市药物数量：1
临床药物数量：6
最高研发阶段：批准上市

SLAMF7产品列表

筛选结果

产品库

在线 (7)

物种

标签

属性

Protein (7)

标记

货号	物种	产品描述
SL7-H5225	Human	Human SLAMF7 / CRACC / CD319 Protein, His Tag (HPLC verified)
SL7-R52H7	Rhesus macaque	Rhesus macaque SLAMF7 / CRACC / CD319 Protein, His Tag (MALS verified)
SL7-H5256	Human	Human SLAMF7 / CRACC / CD319 Protein, Fc Tag
SL7-H82E0	Human	Biotinylated Human SLAMF7 / CRACC / CD319 Protein, Avitag™,His Tag (HPLC verified)
SL7-HF2H7	Human	FITC-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-HP2H3	Human	PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag (Site-specific conjugation)
SL7-M5252	Mouse	Mouse SLAMF7 / CRACC / CD319 Protein, Mouse IgG2a Fc Tag, low endotoxin

SLAMF7分子别名

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

SLAMF7分子背景

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7上市药物信息

英文名称	中文名称	研发代码	研发阶段	公司	最早商品名	最早批准国家	最早适应症	最早批准公司	最早批准日期	适应症	临床试验
Elotuzumab		PDL-063; HuLuc-63; BMS-901608	批准上市	艾伯维, 百时美施贵宝	Empliciti	Japan	多发性骨髓瘤	Bristol-Myers Squibb Company	2015-11-30	造血干细胞移植, 血液肿瘤, 浆细胞白血病, 阴燃多发性骨髓瘤, 多发性骨髓瘤, 淋巴瘤	详情

SLAMF7临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
Anti-CD3/Anti-SLAMF7 Bispecific Antibody (University of Virginia)		临床一期	弗吉尼亚大学	多发性骨髓瘤	详情
CS1 Targeted CAR T-cells (Yake Biotechnology)		临床一期	上海雅科生物科技有限公司	多发性骨髓瘤	详情
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology)		临床阶段不明	武汉波睿达生物科技有限公司, 镇宁同济医院	血液肿瘤	详情
SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital)		临床二期	University Hospital Würzburg	多发性骨髓瘤	详情
UCART-CS1	UCART-38; UCART-CS1	临床一期	Cellectis Sa	多发性骨髓瘤	详情
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics)		临床一期	归气丹生物医药（香港）有限公司	多发性骨髓瘤	详情

会议日历

会议一览

SLAMF7